Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aethlon (AEMD)
:AEMD
Holding AEMD?
Track your performance easily
AEMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.24 - $2.10
Previous CloseN/A
Volume1.62M
Average Volume (3M)6.21M
Market Cap
$9.98M
Enterprise Value$439.87K
Total Cash (Recent Filing)$1.56M
Total Debt (Recent Filing)$519.20K
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Feb 17, 2025EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.85
Shares Outstanding13,961,998
10 Day Avg. Volume1,921,140
30 Day Avg. Volume6,205,899
Standard Deviation0.59
R-Squared0.02
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.04
Forecast
1Y Price Target
$7.00Price Target Upside885.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Aethlon Medical News
PremiumCompany Announcements
Aethlon Medical Reports Progress in Oncology Trials
PremiumCompany Announcements
Aethlon Medical Advances Oncology Trials and Global Expansion
PremiumCompany Announcements
Aethlon Medical Appoints James B. Frakes as CEOBulls Say, Bears Say
Bulls Say
Clinical TrialsThe company is making progress with its clinical trials, having enrolled the first two patients in the Hemopurifier trial for cancer patients with solid tumors.
Research And DevelopmentHemopurifier treatment could enhance the response to anti-PD-1 therapy, as it has shown in vitro to reduce exosomes from the plasma of cancer patient blood samples.
Therapeutic EfficacyPrevious results showed that the Hemopurifier reduced hepatitis C virus load by 57%, comparable to standard-of-care therapies, suggesting its potential effectiveness.
Bears Say
Product ApprovalThere is uncertainty regarding the potential approval and commercialization of the Hemopurifier in the oncology and organ transplant markets.
RevenueThe company reported no revenue recognition for the quarter and does not forecast any revenue recognition for FY25 or FY26.
Stock RecommendationThe recommendation is to maintain a Hold rating and not to purchase AEMD shares at this time based on a balanced risk/reward analysis.
---
Options Prices
Currently, No data available
---
Ownership Overview
2.22% Insiders
0.29% Mutual Funds
0.12% Other Institutional Investors
97.21% Public Companies and Individual Investors
AEMD FAQ
What was Aethlon’s price range in the past 12 months?
Aethlon lowest stock price was $0.24 and its highest was $2.10 in the past 12 months.
What is Aethlon’s market cap?
Aethlon’s market cap is $9.98M.
When is Aethlon’s upcoming earnings report date?
Aethlon’s upcoming earnings report date is Feb 17, 2025 which is in 30 days.
How were Aethlon’s earnings last quarter?
Aethlon released its earnings results on Nov 13, 2024. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.195 by -$0.005.
Is Aethlon overvalued?
According to Wall Street analysts Aethlon’s price is currently Undervalued.
Does Aethlon pay dividends?
Aethlon does not currently pay dividends.
What is Aethlon’s EPS estimate?
Aethlon’s EPS estimate is -0.2.
How many shares outstanding does Aethlon have?
Aethlon has 13,961,998 shares outstanding.
What happened to Aethlon’s price movement after its last earnings report?
Aethlon reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.195. Following the earnings report the stock price went down -2.439%.
Which hedge fund is a major shareholder of Aethlon?
Currently, no hedge funds are holding shares in AEMD
---
Company Description
Aethlon
Aethlon Medical, Inc. is a therapeutic technology company, which focuses on addressing global health and biodefense needs. It develops Aethlon Hemopurifier, a medical device that targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The firm operates through two segments: Aethlon and ESI. The Aethlon segment involves in therapeutic business activities. The ESI segment consists of diagnostic business activities. The company was founded by James A. Joyce in May 1998 and is headquartered in San Diego, CA.
---
AEMD Earnings Call
Q2 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights Aethlon Medical's significant progress in oncology trials and successful expense reductions. However, financial challenges persist with a notable net loss, and there are delays in trial enrollments in India. Despite these concerns, the advancements in the oncology program and strategic cost management efforts are promising.Read More>---
AEMD Stock 12 Month Forecast
Average Price Target
$7.00
▲(885.92% Upside)
Technical Analysis
Best Analysts Covering AEMD
1 Year
1 Year Success Rate
1/9 ratings generated profit
1 Year Average Return
-52.86%
reiterated a buy rating 2 months ago
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -52.86% per trade.
---